The molecular basis of adrenocortical cancer

Cancer Genetics

Volumn 205, Issue 4, 2012, Pages 131-137

  Lehmann, Tomasz ^a   Wrzesinski, Tomasz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adrenal; Cancer; Gene expression; Microarray

Indexed keywords

ALDOSTERONE; ANTIBODY; COMPLEMENTARY RNA; HYDROCORTISONE; ISOQUINOLINE DERIVATIVE; MICRORNA; MITOTANE; RETINOIC ACID; TRANSCRIPTOME; WNT PROTEIN; SEX HORMONE;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; COMPUTER ASSISTED TOMOGRAPHY; CTNNB1 GENE; DRUG MECHANISM; GENE EXPRESSION; GENETIC ANALYSIS; HISTOLOGY; HUMAN; IGF2 GENE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEROIDOGENESIS; SYMPTOM; TP53 GENE; TUMOR SUPPRESSOR GENE; ADRENAL GLAND; BLOOD; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; METHODOLOGY; PATHOLOGY; SECRETION; SURVIVAL RATE; URINE;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLANDS; ADRENOCORTICAL ADENOMA; ADRENOCORTICAL CARCINOMA; GENE EXPRESSION PROFILING; GONADAL STEROID HORMONES; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SURVIVAL RATE; TRANSCRIPTOME;

EID: 84862727987     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.02.009     Document Type: Review

References (70)

1. Mannelli M., Colagrande S., Valeri A., et al. Incidental and metastatic adrenal masses. Semin Oncol 2010, 37:649-661.
2. Angeli A., Osella G., Ali A., et al. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res 1997, 47:279-283.
3. Grumbach M.M., Biller B.M., Braunstein G.D., et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 2003, 138:424-429.
4. Luton J.P., Martinez M., Coste J., et al. Outcome in patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center. Eur J Endocrinol 2000, 143:111-117.
5. Allolio B., Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006, 91:2027-2037.
6. Kirschner L.S. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 2006, 91:14-21.
7. Fassnacht M., Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2009, 23:273-289.
8. Icard P., Chapuis Y., Andreassian B., et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992, 112:972-979. discussion 979-980.
9. Mantero F., Terzolo M., Arnaldi G., et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 2000, 85:637-644. Study Group on Adrenal Tumors of the Italian Society of Endocrinology.
10. Abiven G., Coste J., Groussin L., et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006, 91:2650-2655.
11. Weiss L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984, 8:163-169.
12. Tissier F., Cavard C., Groussin L., et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005, 65:7622-7627.
13. Barreau O., de Reynies A., Wilmot-Roussel H., et al. Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: an integrated genomic approach. J Clin Endocrinol Metab 2012, 97:E301-E311.
14. Nakazumi H., Sasano H., Iino K., et al. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol 1998, 11:1165-1170.
15. Schmitt A., Saremaslani P., Schmid S., et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 2006, 49:298-307.
16. Velazquez-Fernandez D., Laurell C., Geli J., et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 2005, 138:1087-1094.
17. de Reynies A., Assie G., Rickman D.S., et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009, 27:1108-1115.
18. Giordano T.J., Kuick R., Else T., et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009, 15:668-676.
19. Laurell C., Velazquez-Fernandez D., Lindsten K., et al. Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur J Endocrinol 2009, 161:141-152.
20. Bassett M.H., Mayhew B., Rehman K., et al. Expression profiles for steroidogenic enzymes in adrenocortical disease. J Clin Endocrinol Metab 2005, 90:5446-5455.
21. Lenzini L., Seccia T.M., Aldighieri E., et al. Heterogeneity of aldosterone-producing adenomas revealed by a whole transcriptome analysis. Hypertension 2007, 50:1106-1113.
22. Wang T., Satoh F., Morimoto R., et al. Gene expression profiles in aldosterone-producing adenomas and adjacent adrenal glands. Eur J Endocrinol 2011, 164:613-619.
23. Fallo F., Pezzi V., Barzon L., et al. Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. Eur J Endocrinol 2002, 147:795-802.
24. Saner-Amigh K., Mayhew B.A., Mantero F., et al. Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. J Clin Endocrinol Metab 2006, 91:1136-1142.
25. Ye P., Mariniello B., Mantero F., et al. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol 2007, 195:39-48.
26. Tadjine M., Lampron A., Ouadi L., et al. Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD). Clin Endocrinol (Oxf) 2008, 69:367-373.
27. Søreide J.A., Brabrand K., Thoresen S.O. Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 1992, 16:663-667. discussion 668.
28. Kasperlik-Zaluska A.A., Migdalska B.M., Zgliczynski S., et al. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995, 75:2587-2591.
29. Hanna N.N., Kenady D.E. Advances in the management of adrenal tumors. Curr Opin Oncol 2000, 12:49-53.
30. de Fraipont F., El Atifi M., Cherradi N., et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 2005, 90:1819-1829.
31. Sidhu S., Marsh D.J., Theodosopoulos G., et al. Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 2002, 87:3467-3474.
32. Kjellman M., Kallioniemi O.P., Karhu R., et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 1996, 56:4219-4223.
33. Russell A.J., Sibbald J., Haak H., et al. Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage. Br J Cancer 1999, 81:684-689.
34. Zhao J., Speel E.J., Muletta-Feurer S., et al. Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am J Pathol 1999, 155:1039-1045.
35. Dohna M., Reincke M., Mincheva A., et al. Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 2000, 28:145-152.
36. Tombol Z., Szabo P.M., Molnar V., et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer 2009, 16:895-906.
37. Lombardi C.P., Raffaelli M., Pani G., et al. Gene expression profiling of adrenal cortical tumors by cDNA macroarray analysis. Results of a preliminary study. Biomed Pharmacother 2006, 60:186-190.
38. Szabo P.M., Tamasi V., Molnar V., et al. Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed. Oncogene 2010, 29:3163-3172.
39. Reincke M., Mora P., Beuschlein F., et al. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. J Clin Endocrinol Metab 1997, 82:3054-3058.
40. Reincke M., Beuschlein F., Menig G., et al. Localization and expression of adrenocorticotropic hormone receptor mRNA in normal and neoplastic human adrenal cortex. J Endocrinol 1998, 156:415-423.
41. Slater E.P., Diehl S.M., Langer P., et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 2006, 154:587-598.
42. West A.N., Neale G.A., Pounds S., et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res 2007, 67:600-608.
43. Lu L., Suzuki T., Yoshikawa Y., et al. Nur-related factor 1 and nerve growth factor-induced clone B in human adrenal cortex and its disorders. J Clin Endocrinol Metab 2004, 89:4113-4118.
44. el Akawi Z., Napoli J.L. Rat liver cytosolic retinal dehydrogenase: comparison of 13-cis-, 9-cis-, and all-trans-retinal as substrates and effects of cellular retinoid-binding proteins and retinoic acid on activity. Biochemistry 1994, 33:1938-1943.
45. Soon P.S., Gill A.J., Benn D.E., et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer 2009, 16:573-583.
46. Ragazzon B., Libe R., Gaujoux S., et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 2010, 70:8276-8281.
47. Hermsen I.G., Fassnacht M., Terzolo M., et al. Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011, 96:1844-1851.
48. Ilvesmaki V., Kahri A.I., Miettinen P.J., et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 1993, 77:852-858.
49. Mesiano S., Mellon S.H., Jaffe R.B. Mitogenic action, regulation, and localization of insulin-like growth factors in the human fetal adrenal gland. J Clin Endocrinol Metab 1993, 76:968-976.
50. Gicquel C., Bertagna X., Le Bouc Y. Recent advances in the pathogenesis of adrenocortical tumours. Eur J Endocrinol 1995, 133:133-144.
51. Gicquel C., Raffin-Sanson M.L., Gaston V., et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 1997, 82:2559-2565.
52. Gicquel C., Bertagna X., Gaston V., et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001, 61:6762-6767.
53. DeChiara T.M., Robertson E.J., Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991, 64:849-859.
54. Giordano T.J., Thomas D.G., Kuick R., et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003, 162:521-531.
55. l'Allemand D., Penhoat A., Lebrethon M.C., et al. Insulin-like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells. J Clin Endocrinol Metab 1996, 81:3892-3897.
56. El Wakil A., Lalli E. The Wnt/beta-catenin pathway in adrenocortical development and cancer. Mol Cell Endocrinol 2011, 332:32-37.
57. Schinner S., Willenberg H.S., Krause D., et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes (Lond) 2007, 31:864-870.
58. Gaujoux S., Tissier F., Groussin L., et al. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 2008, 93:4135-4140.
59. Caron de Fromentel C., Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992, 4:1-15.
60. Wagner J., Portwine C., Rabin K., et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 1994, 86:1707-1710.
61. Varley J.M., McGown G., Thorncroft M., et al. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet 1999, 65:995-1006.
62. Lin S.R., Lee Y.J., Tsai J.H. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 1994, 78:483-491.
63. Barzon L., Chilosi M., Fallo F., et al. Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur J Endocrinol 2001, 145:207-212.
64. Yano T., Linehan M., Anglard P., et al. Genetic changes in human adrenocortical carcinomas. J Natl Cancer Inst 1989, 81:518-523.
65. Schteingart D.E., Doherty G.M., Gauger P.G., et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005, 12:667-680.
66. Libe R., Fratticci A., Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007, 14:13-28.
67. Cobb W.S., Kercher K.W., Sing R.F., et al. Laparoscopic adrenalectomy for malignancy. Am J Surg 2005, 189:405-411.
68. Baehner F.L., Lee M., Demeure M.J., et al. Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy. J Surg Oncol 2011, 103:563-573.
69. Fassnacht M., Libe R., Kroiss M., et al. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011, 7:323-335.
70. Doghman M., Madoux F., Hodder P., et al. Identification and characterization of steroidogenic factor-1 inverse agonists. Methods Enzymol 2010, 485:3-23.